Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1
- Jiansong Wu
- Qiang Niu
- Jie Yuan
- Xiaodan Xu
- Liuxia Cao
Affiliations: Department of Infectious Diseases, General Hospital of the People's Liberation Army Rocket Force, Beijing 100088, P.R. China
- Published online on: October 7, 2019 https://doi.org/10.3892/etm.2019.8080
Copyright: © Wu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Although it is known that Phenazine biosynthesis‑like domain‑containing protein (PBLD) expression is downregulated in hepatocellular carcinoma (HCC), its biological function is unclear. Additionally, no agents capable of upregulating PBLD exist. In the current study, the relationship between PBLD and HCC was analyzed using clinicopathological specimens. A HCC cell model, microarray analysis and an animal model were used to verify the therapeutic effect of cedrelone on HCC. The present study demonstrated that PBLD inhibited HCC progression. Furthermore, the present study revealed that cedrelone possessed treated‑HCC capabilities via targeted PBLD overexpression. The epithelial‑mesenchymal transition phenotype and growth rate were inhibited and the apoptosis ratio was promoted by cedrelone following PBLD overexpression. The Ras and Ras‑proximate‑1 signaling pathways were also determined to be regulated by cedrelone via PBLD activation in HCC. PBLD may therefore be an independent predictor of HCC progression and a novel target for HCC treatment. Additionally, the PBLD activator, cedrelone, may be a potential drug for HCC treatment in the future.